STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…

Biosimilars 363

Biosimilars Drug Pricing Documentation Pharmaceutical Companies 363

BioPharma Dive

JANUARY 10, 2024

In the background, a contentious drug pricing law looms. Many drugmakers hope to compete in obesity, while others seek to win oncology’s next era.

Drug Pricing 117

Drug Pricing 117

Drug Channels

MARCH 19, 2024

I am pleased to announce our new 2024 Economic Report on U.S. Download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) HMP Global’s Drug Channels Institute releases ‘2024 Economic Report on U.S. The 2024 Economic Report on U.S. Read on for some additional details.

Drug Pricing 70

Drug Pricing 70

Drug Channels

MARCH 7, 2024

On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. prescription drug channels. prescription drug channels. Review pricing/license options and place a preorder. Pharmacies and Pharmacy Benefit Managers.

Drug Pricing 76

Drug Pricing 76

STAT

FEBRUARY 15, 2024

The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election.

Drug Pricing 254

Drug Pricing 254

Pharmaceutical Technology

FEBRUARY 15, 2024

In 2023, Japan approved the outlines of its drug pricing and repricing reform for NHI-listed drugs that will take effect in FY 2024 and FY 2025.

Drug Pricing 52

Drug Pricing 52

pharmaphorum

JANUARY 10, 2024

Policy strategists, like the experts at Avalere, are essential in navigating the seismic policy changes expected in 2024. This includes areas such as drug pricing and patient access. Learn more about their insights and recommendations for the future.

Drug Pricing 52

Drug Pricing 52

STAT

DECEMBER 27, 2023

As another year comes to an end and the world seems to hit the proverbial pause button, the temptation to look ahead is too great to ignore. After all, this is what journalists like to do as the calendar turns another page. So once again, we will take a whack at identifying some of the most noteworthy developments to watch.

Drug Pricing 273

Drug Pricing 273

STAT

FEBRUARY 1, 2024

On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing.

Drug Pricing 295

Drug Pricing Vaccines Communication Drug Development 295

Definitive Healthcare

FEBRUARY 23, 2024

Resource Type E-Books & How-To Guides Blog How-To Guide Healthcare Insight Medical claims 101: What you need to know How to sell effectively to healthcare facilities and executives using the right… Hospital payor mix by state Image Image Image ","nextArrow":" ","appendArrows":".coh-slider-nav-bottom","dots":false,"draggable":true,"swipe":true,"fade":false,"vertical":false,"speed":700,"cssEase":"ease","pauseOnHover":false,"pauseOnDotsHover":false,"autoplay":false,"rows":0},"sm":{"slidesToShow":2,

Drug Pricing 52

Drug Pricing Hospitals Drug Development 52

STAT

AUGUST 10, 2023

By doing so, the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based on when the drug first goes on the market. Novo Nordisk will continue to restrict U.S. demand , STAT notes. The

Drug Pricing 245

Drug Pricing Diabetes 245

Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.

Drug Pricing 75

Drug Pricing Biosimilars 75

Drug Channels

DECEMBER 5, 2023

The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drug pricing system. to 1:30 p.m.

Drug Pricing 81

Drug Pricing Hospitals 81

STAT

JANUARY 11, 2024

JPM Week is finally drawing to a close, sending the drug industry’s many financiers scattering from San Francisco to their respective homes and ski destinations. In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout.

Drug Pricing 263

Drug Pricing Drug Development 263

STAT

OCTOBER 1, 2022

Amylyx did not immediately disclose how much it will charge for Relyvrio, but the company is conducting a larger, longer clinical trial to confirm the benefits, with data expected in late 2023 or early 2024. In a rare commitment, the company has promised to remove the drug from the market if that study is not successful.

Drug Pricing 246

Drug Pricing 246

pharmaphorum

APRIL 13, 2022

Unfortunately, the current drug pricing bill fails to take a holistic approach to addressing a system that drives affordability challenges for patients. The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Drug Pricing 128

Drug Pricing Diabetes Biosimilars 128

STAT

JANUARY 4, 2024

Damian here with an in-depth preview of a certain annual biotech conference, a look at the cutting edge of obesity drug development, and year’s first IPO filing. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, everyone.

Drug Development 247

Drug Development Drug Pricing 247

Pharmaceutical Technology

APRIL 26, 2024

The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 12, 2024

Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We’re offering special discounted pricing if you order before April 7, 2024. Pharmacies and Pharmacy Benefit Managers. For 2023, DCI estimates that U.S. to 1:30 p.m.

Drug Pricing 79

Drug Pricing 79

Putting Patients First Blog

SEPTEMBER 11, 2023

NHC comments on the 2024 Physician Fee Schedule September 11, 2023 By: Allen Pinn, Coordinator, Policy On July 13, the Centers for Medicare & Medicaid Services (CMS) released their proposed rule for the 2024 Physician Fee Schedule. Below is a summary of the NHC’s comments submitted September 11, 2023.

Drug Pricing 59

Drug Pricing 59

Digital Pharmacist

APRIL 25, 2023

f you’re an independent pharmacy owner or pharmacist, you’re probably aware of the upcoming changes to DIR fees that will take effect in 2024. In this blog post, we will discuss the evolution of DIR fees leading up to the DIR fee changes coming in 2024, and the pros and cons independent pharmacies owners should prepare for.

Independent Pharmacies 98

Independent Pharmacies Drug Utilization Review Drug Pricing Pharmacy Management 98

Pharma in Brief

JANUARY 10, 2024

We also flag what to watch out for in 2024. Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

Drug Channels

FEBRUARY 7, 2024

And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.

Drug Pricing 91

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 91

Big Molecule Watch

JULY 18, 2023

On June 30, 2023, the Centers for Medicare & Medicaid Services (CMS) released its updated final program guidance covering the Inflation Reduction Act’s Medicare Drug Price Negotiation Program for the first round of negotiations, which will occur during 2023 and 2024 and result in prices that will be effective beginning in 2026.

Drug Pricing 52

Drug Pricing 52

Pharma in Brief

FEBRUARY 16, 2024

Next steps The Board has previously indicated that it intends to finalize new Guidelines before the end of 2024. The Report does not address the written submissions; the PMPRB advises that it will be reviewing these separately.

Drug Pricing 52

Drug Pricing 52

Big Molecule Watch

NOVEMBER 6, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. For drugs selected for the first year of the Program, negotiations will end by August 1, 2024.

Drug Pricing 67

Drug Pricing Biosimilars 67

Pharma in Brief

SEPTEMBER 28, 2023

As explained in greater detail below, consultation on replacement guidelines is now expected to take place in 2024. The Amendments As we reported , the original Interim Guidance did not contemplate price review for New Medicines during the Interim Period.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 21, 2024

How will the most consequential change in federal drug pricing policy affect drug pricing? Find out during Drug Channel Implications of the Inflation Reduction Act , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Drug Pricing 97

Drug Pricing 97

Drug Channels

MARCH 18, 2024

Informa Connect’s Life Sciences Pricing & Contracting USA May 21-23, 2024 | New Orleans Drug Channels readers save 10% with code 24DRCH10* Whether your daily focus is on Medicaid, Government Pricing, 340B, Drug Price Transparency, Commercial Contracting or Chargebacks , we have you covered!

Drug Pricing 75

Drug Pricing 75

Pharma in Brief

NOVEMBER 12, 2023

The Board previously indicated that a second phase of consultation in 2024 would focus on the development of new Guidelines. The scoping paper states that the Board intends to finalize new Guidelines in 2024. The Board indicated that a “What We Heard” document will be released in 2024.

Drug Pricing 52

Drug Pricing Documentation 52

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Drug Pricing 83

Drug Pricing Biosimilars 83

Pharma in Brief

OCTOBER 26, 2023

The Board previously indicated that the second stage of consultation, focused on the development of new guidelines, will take place in 2024.

Drug Pricing 52

Drug Pricing 52

STAT

MARCH 3, 2023

… Now that Eli Lilly slashed the price for some of its insulin products, the moves raised questions about what will happen to other efforts to provide low-cost insulin, Kaiser Health News explains. And the Mark Cuban Cost Plus Drug Co. But drug=pricing experts predict Lilly’s moves will not undercut those efforts.

Drug Pricing 246

Drug Pricing Biosimilars 246

Drug Channels

DECEMBER 15, 2023

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. My topic #9 for 2024: The Battle Over 340B Gets Even Messier. Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. billion (+$2.6

Drug Pricing 79

Drug Pricing Hospitals 79

FDA Law Blog: Biosimilars

JUNE 16, 2023

Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers.

Drug Pricing 45

Drug Pricing Biosimilars Dosage Documentation 45

Drug Channels

APRIL 1, 2024

Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drug pricing system. Tomorrow on Drug Channels , I’ll delve into the pros and cons of this new approach. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Drug Pricing 85

Drug Pricing Hospitals 85

Putting Patients First Blog

MARCH 21, 2024

Inflation Reduction Act Update March 21, 2024 By: Allen Pinn, Coordinator, Policy The Inflation Reduction Act (IRA) was signed into law on August 16, 2022, and has garnered mass attention from the health care community. As implementation of the law unfolds, the National Health Council (NHC) will routinely publish policy updates.

Drug Pricing 52

Drug Pricing 52